A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Gastroenterology

• Publication date

  2008-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1053/j.gastro.2008.03.020PMID 18485901
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine.

  2007cited by this paper
• Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer

  2007cited by this paper
• Immune surveillance of tumors.

  2007cited by this paper
• Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection.

  2007cited by this paper
• Unmasking of α-Fetoprotein-Specific CD4+ T Cell Responses in Hepatocellular Carcinoma Patients Undergoing Embolization1

  2007cited by this paper
• Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression.

  2006cited by this paper
• Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host.

  2006cited by this paper
• Immunotherapy of hepatocellular carcinoma.

  2006cited by this paper
• Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma.

  2006cited by this paper
• Genetically induced pancreatic adenocarcinoma is highly immunogenic and causes spontaneous tumor-specific immune responses.

  2006cited by this paper
• Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells.

  2006cited by this paper
• All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients.

  2006cited by this paper
• “Alternatively Activated” Dendritic Cells Preferentially Secrete IL-10, Expand Foxp3+CD4+ T Cells, and Induce Long-Term Organ Allograft Survival in Combination with CTLA4-Ig1

  2006cited by this paper
• Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients.

  2006cited by this paper
• Regulatory T cells, tumour immunity and immunotherapy

  2006cited by this paper
• Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function

  2006cited by this paper
• Reduction of Myeloid-Derived Suppressor Cells and Induction of M1 Macrophages Facilitate the Rejection of Established Metastatic Disease1

  2005cited by this paper
• Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion.

  2005cited by this paper
• Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma.

  2005cited by this paper
• Spontaneous Tumor-Specific Humoral and Cellular Immune Responses to NY-ESO-1 in Hepatocellular Carcinoma

  2004cited by this paper
• Arginase I Production in the Tumor Microenvironment by Mature Myeloid Cells Inhibits T-Cell Receptor Expression and Antigen-Specific T-Cell Responses

  2004cited by this paper
• Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

  2004cited by this paper
• Induction of FOXP3‐expressing regulatory CD4pos T cells by human mature autologous dendritic cells

  2004cited by this paper
• L-arginine metabolism in myeloid cells controls T-lymphocyte functions.

  2003cited by this paper
• Modified myeloid dendritic cells act as regulatory dendritic cells to induce anergic and regulatory T cells.

  2003cited by this paper
• Peptide-beta2-microglobulin-MHC fusion molecules bind antigen-specific T cells and can be used for multivalent MHC-Ig complexes.

  2002cited by this paper
• Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients.

  2001cited by this paper
• Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in Cancer1

  2001cited by this paper
• Immunotherapy in hepatocellular carcinoma.

  2000cited by this paper
• Induction of Interleukin 10–Producing, Nonproliferating Cd4+ T Cells with Regulatory Properties by Repetitive Stimulation with Allogeneic Immature Human Dendritic Cells

  2000cited by this paper
• Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34(+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor.

  1995cited by this paper

• Therapeutic potential of hookworm proteins in promoting regulatory immune responses to modulate Trypanosoma cruzi induced liver inflammation and oxidative stress

  2026cites this paper
• Interactions and communications in hepatocellular carcinoma: Potential targets for chemo/radiosensitization.

  2026cites this paper
• Tumor microenvironment in gastric cancer immune tolerance and its therapeutic relevance in immunomodulation (Review)

  2026cites this paper
• Remodeling the tumor dormancy ecosystem to prevent recurrence and metastasis

  2026cites this paper
• Cyclophosphamide-Mediated Induction of Myeloid-Derived Suppressor Cells In Vivo: Kinetics of Accumulation, Immune Profile, and Immunomodulation by Oleanane-Type Triterpenoids

  2026cites this paper
• Spatial heterogeneity of the hepatocellular carcinoma microenvironment determines the efficacy of immunotherapy

  2025cites this paper
• Impact of Reduction in Myeloid‐derived Suppressor Cells by Wilms’ Tumor 1‐targeted Dendritic Cell Vaccines on Clinical Outcomes in Acute Leukemia Patients

  2025cites this paper
• Altering the Gut Microbiome and Tumor Microenvironment in Advanced Liver Cancer: A Phase II Study of Nivolumab, Tadalafil and Oral Vancomycin in Patients with Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer from Colorectal or Pancreatic Cancers.

  2025cites this paper
• The role of immune regulation in HBV infection and hepatocellular carcinogenesis

  2025cites this paper
• MERTK inhibition improves therapeutic efficacy of immune checkpoint inhibitors in hepatocellular carcinoma

  2025cites this paper
• The Emerging Challenge of Non-Cirrhotic MASLD-Related Hepatocellular Carcinoma: Etiology, Immunopathology, and Precision Oncology.

  2025cites this paper
• Unraveling the obesity paradox in hepatocellular carcinoma: relative role of elevated body mass index on detrimental effects of postoperative complications.

  2025cites this paper
• The important role of myeloid-derived suppressor cells: From hepatitis to liver cancer.

  2025cites this paper
• Hepatocellular Carcinoma – from Immunobiology to Immunotherapy

  2025cites this paper
• Improving immunotherapy for the treatment of hepatocellular carcinoma: learning from patients and preclinical models

  2025cites this paper
• The immunosuppressive role of MDSCs in HCC: mechanisms and therapeutic opportunities

  2025cites this paper
• Trained immunity in pregnancy: Impact on maternal-fetal outcomes and mechanistic insights.

  2025cites this paper
• Immunomodulatory role of vitamin D and emerging immunotherapies in hepatocellular carcinoma

  2025cites this paper
• Immune microenvironment and immunotherapy in hepatocellular carcinoma: mechanisms and advances

  2025cites this paper
• Mechanical microenvironment and its role in hepatocellular carcinoma oncogenesis and progression.

  2025cites this paper
• Dual regulatory role of natural killer T cells during development of hepatocellular carcinoma

  2025cites this paper
• Advancing Adjuvant Immunotherapy in Hepatocellular Carcinoma: A Comprehensive Review

  2025cites this paper
• Immune microenvironment in hepatocellular carcinoma: from pathogenesis to immunotherapy

  2025cites this paper
• Multi-Omics Profiling of Intercellular Immunometabolic Heterogeneity highlights in Lung Cancer: Crosstalk mechanisms and Resistance in the Tumor-Immune Interface.

  2025cites this paper
• Immune-related adverse events in patients with low baseline serum IL-6 treated with durvalumab plus tremelimumab for hepatocellular carcinoma: a case series

  2025cites this paper
• Neoadjuvant immunotherapy for resectable primary liver cancer (Review)

  2025cites this paper
• Delineation of monocytic and early‐stage myeloid‐derived suppressor cells in the peripheral blood of patients with hepatocarcinoma

  2025influential citation
• Decreased circulating myeloid-derived suppressor cell count at the engraftment is one of the risk factors for multiple myeloma relapse after autologous hematopoietic stem cell transplantation

  2024cites this paper
• Immunosuppressive tumor microenvironment in the progression, metastasis, and therapy of hepatocellular carcinoma: from bench to bedside

  2024cites this paper
• Immunotherapy for hepatocellular carcinoma

  2024cites this paper
• Myeloid-derived suppressor cells in cancer: Current knowledge and future perspectives.

  2024cites this paper
• Targeting Myeloid-Derived Suppressor Cells via Dual-Antibody Fluorescent Nanodiamond Conjugate

  2024cites this paper
• Regulatory T cells and immune escape in HCC: understanding the tumor microenvironment and advancing CAR-T cell therapy

  2024cites this paper
• Hepatitis B virus‐related hepatocellular carcinoma exhibits distinct intratumoral microbiota and immune microenvironment signatures

  2024cites this paper
• Anti-stromal nanotherapeutics for hepatocellular carcinoma.

  2024cites this paper
• A preliminary study of IgG4 expression and its prognostic significance in oral squamous cell carcinoma

  2024cites this paper
• Complex Role of Regulatory T Cells (Tregs) in the Tumor Microenvironment: Their Molecular Mechanisms and Bidirectional Effects on Cancer Progression

  2024cites this paper
• Radio-Immunomics in Hepatocellular Carcinoma: Unraveling the Tumor Immune Microenvironment

  2024cites this paper
• Exploiting the immune system in hepatic tumor targeting: Unleashing the potential of drugs, natural products, and nanoparticles.

  2024cites this paper
• EP2 and EP4 blockade prevents tumor-induced suppressive features in human monocytic myeloid-derived suppressor cells

  2024cites this paper
• The Roles of Myeloid-Derived Suppressor Cells in Liver Disease

  2024cites this paper
• Hepatic recruitment of myeloid-derived suppressor cells upon liver injury promotes both liver regeneration and fibrosis

  2024cites this paper
• Myeloid-derived suppressor cells in cancer: therapeutic targets to overcome tumor immune evasion

  2024cites this paper
• Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma

  2024cites this paper
• CKLF instigates a “cold” microenvironment to promote MYCN-mediated tumor aggressiveness

  2024cites this paper
• Trained innate immunity as a potential link between preeclampsia and future cardiovascular disease

  2024cites this paper
• 铁死亡调控肝细胞癌及其肿瘤免疫研究进展

  2024cites this paper
• Engineering immune response to regulate cardiovascular disease and cancer.

  2024cites this paper
• Myeloid-derived suppressor cells: A new emerging player in endometriosis.

  2023cites this paper
• Xuanhusuo powder has an anti-breast cancer effect by inhibiting myeloid-derived suppressor cell differentiation in the spleen of mice through down-regulating granulocyte colony stimulating factor.

  2023cites this paper
• Inducible nitric oxide synthase-expressing myeloid-derived suppressor cells regulated by interleukin 35 contribute to the pathogenesis of psoriasis

  2023cites this paper
• SPATS2 is correlated with cell cycle progression and immune cells infiltration in hepatocellular carcinoma

  2023cites this paper
• Effect of Proton Therapy on Tumor Cell Killing and Immune Microenvironment for Hepatocellular Carcinoma

  2023cites this paper
• Myeloid-derived suppressor cells: key immunosuppressive regulators and therapeutic targets in hematological malignancies

  2023cites this paper
• Distinctive Dynamics and Functions of the CD4+CD25+FOXP3+ Regulatory T Cell Population in Patients with Severe and Mild COVID-19.

  2023cites this paper
• Liver metastasis from colorectal cancer: pathogenetic development, immune landscape of the tumour microenvironment and therapeutic approaches

  2023cites this paper
• Targeting ferroptosis in hepatocellular carcinoma

  2023cites this paper
• Radiation and Immune Checkpoint Inhibitors: Combination Therapy for Treatment of Hepatocellular Carcinoma

  2023cites this paper
• Functional Flow Cytometry to Predict PD‐L1 Conformational Changes

  2023cites this paper
• Role of immune responses for development of NAFLD-associated liver cancer and prospects for therapeutic modulation.

  2023cites this paper
• Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment

  2023cites this paper
• Innate-like T lymphocytes in chronic liver disease

  2023cites this paper
• Myeloid-derived suppressor cells: Key immunosuppressive regulators and therapeutic targets in cancer.

  2023cites this paper
• Could the Crosstalk Between Myeloid-Derived-Suppressor Cells and Regulatory T Cells Have a Role in Beta-Thalassemia?

  2023cites this paper
• HDAC inhibitors enhance the anti-tumor effect of immunotherapies in hepatocellular carcinoma

  2023cites this paper
• HIF‐1α targeted deletion in myeloid cells decreases MDSC accumulation and alters microbiome in neonatal mice

  2023cites this paper
• The Role of TLR4 in the Immunotherapy of Hepatocellular Carcinoma: Can We Teach an Old Dog New Tricks?

  2023cites this paper
• Biomarkers for immunotherapy of hepatocellular carcinoma

  2023cites this paper
• Peritoneal Immunity in Liver Disease

  2023cites this paper
• Fluorescent Detection of Peroxynitrite Produced by Myeloid-Derived Suppressor Cells in Cancer and Inhibition by Dasatinib.

  2023cites this paper
• Crosstalk between N6-methyladenosine (m6A) modification and noncoding RNA in tumor microenvironment

  2023cites this paper
• Hepatocellular carcinoma (HCC) immunotherapy by anti-PD-1 monoclonal antibodies: A rapidly evolving strategy.

  2023cites this paper
• The role of myeloid-derived suppressor cells in liver cancer

  2023influential citation
• Clinical significance of FBXO43 in hepatocellular carcinoma and its impact on tumor cell proliferation, migration and invasion

  2023cites this paper
• Insights into N6-methyladenosine (m6A) modification of noncoding RNA in tumor microenvironment

  2023cites this paper
• Neutrophil diversity in inflammation and cancer

  2023cites this paper
• Radiofrequency ablation combined with toripalimab for recurrent hepatocellular carcinoma: A prospective controlled trial

  2023cites this paper
• Myeloid-derived suppressor cells in multiple myeloma patients at the immune recovery and after high-dose chemotherapy and hematopoietic stem cell transplantation

  2022cites this paper
• Polymorphonuclear Myeloid-Derived Suppressor Cells Are Abundant in Peripheral Blood of Cancer Patients and Suppress Natural Killer Cell Anti-Tumor Activity

  2022cites this paper
• An immune infiltration-related long non-coding RNAs signature predicts prognosis for hepatocellular carcinoma

  2022cites this paper
• N1 versus N2 and PMN‐MDSC: A critical appraisal of current concepts on tumor‐associated neutrophils and new directions for human oncology

  2022cites this paper
• Lower frequency of MDSCs was significantly related to functional cure in CHB patients treated with peginterferon

  2022cites this paper
• Therapeutic implications of the tumor microenvironment in ovarian cancer patients receiving PD-1/PD-L1 therapy

  2022cites this paper
• Tumor Microenvironment in Hepatocellular Carcinoma: Key Players for Immunotherapy

  2022cites this paper
• The immunosuppressive tumor microenvironment in hepatocellular carcinoma-current situation and outlook.

  2022cites this paper
• Perspectives for novel therapeutic concepts in hepatocellular carcinoma targeting the stromal and innate immune microenvironment

  2022cites this paper
• The immune landscape of hepatocellular carcinoma-where we are?

  2022cites this paper
• Targeted delivery and reprogramming of myeloid-derived suppressor cells (MDSCs) in cancer

  2022cites this paper
• Dominant immune cells in pregnancy and pregnancy complications: T helper cells (TH1/TH2, TH17/Treg cells), NK cells, MDSCs, and the immune checkpoints

  2022cites this paper
• Prognostic Factors Contributing to the Survival of Hematopoietic Stem Cell Transplantation in the General Population with Leukemia: a Systematic Review

  2022cites this paper
• Strategies for improving the efficacy of immunotherapy in hepatocellular carcinoma.

  2022cites this paper
• The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma

  2022influential citation
• Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy

  2022cites this paper
• Protein Regulator of Cytokinesis 1 (PRC1) Upregulation Promotes Immune Suppression in Liver Hepatocellular Carcinoma

  2022cites this paper
• Approaches to spatially resolving the tumour immune microenvironment of hepatocellular carcinoma

  2022cites this paper
• Myeloid-Derived Suppressor Cells and CD68+CD163+M2-Like Macrophages as Therapeutic Response Biomarkers Are Associated with Plasma Inflammatory Cytokines: A Preliminary Study for Non-Small Cell Lung Cancer Patients in Radiotherapy

  2022cites this paper
• Synergizing liver systemic treatments with interventional oncology: friend or foe?

  2022cites this paper
• Myeloid-Derived Suppressor Cells in Solid Tumors

  2022cites this paper
• Noncoding RNA-mediated molecular bases of chemotherapy resistance in hepatocellular carcinoma

  2022cites this paper
• Enabling CAR-T cells for solid tumors: Rage against the suppressive tumor microenvironment.

  2022cites this paper